148.01
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Biohaven Pharmaceutical Holding Company Ltd | BHVN | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
148.01 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 79.01 - 151.51 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 148.01 | USD |
Biohaven Pharmaceutical Holding Company Ltd Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 10.58B | 71.49M | 64.59M | $ 462.51M | $ -359.05M | -13.13 | -10.00 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 870.00 | 9.20% |
Biohaven Pharmaceutical News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BHVN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 147.40 | 148.225 | 147.13 | 147.82 | 384,843 | 0.61 | 0.41% |
1 Month | 145.95 | 148.225 | 145.73 | 146.70 | 507,442 | 2.06 | 1.41% |
3 Months | 143.35 | 148.225 | 142.65 | 145.23 | 791,465 | 4.66 | 3.25% |
6 Months | 140.39 | 148.225 | 79.01 | 134.08 | 1,189,397 | 7.62 | 5.43% |
1 Year | 118.97 | 151.51 | 79.01 | 131.37 | 852,193 | 29.04 | 24.41% |
3 Years | 39.64 | 151.51 | 26.56 | 90.30 | 752,289 | 108.37 | 273.39% |
5 Years | 25.31 | 151.51 | 16.5001 | 74.73 | 649,763 | 122.70 | 484.79% |
Biohaven Pharmaceutical Description
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others. |